

# Unsaturated fatty acid composition in serum phospholipids in patients in the acute phase of myocardial infarction

Aleksander Siniarski<sup>1,2</sup>, Paweł Rostoff<sup>1,2</sup>, Radosław Rychlak<sup>2</sup>, Krzysztof Krawczyk<sup>1,2</sup>, Renata Gołębiowska-Wiatrak<sup>1,2</sup>, Magdalena Mostowik<sup>3</sup>, Krzysztof P. Malinowski<sup>4</sup>, Ewa Konduracka<sup>1,2</sup>, Jadwiga Nessler<sup>1,2</sup>, Grzegorz Gajos<sup>1,2</sup>

1 Department of Coronary Disease and Heart Failure, Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

2 John Paul II Hospital, Kraków, Poland

3 Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, John Paul II Hospital, Kraków, Poland

4 Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Kraków, Poland

## KEY WORDS

fatty acid composition, MUFA, myocardial infarction, omega-3 acids, PUFA

## ABSTRACT

**BACKGROUND** Recent improvements in optimal cardiovascular therapy have questioned the beneficial effects of polyunsaturated fatty acids (PUFAs) observed in previous studies.

**AIMS** We investigated the fatty acid (FA) composition in serum phospholipids in patients with an established acute phase of myocardial infarction (MI) and in high-risk patients with stable atherosclerotic cardiovascular disease (CVD).

**METHODS** We studied 83 patients hospitalized within 12 hours from the onset of the first clinical symptoms of MI. As a control group, we assessed 74 patients at high cardiovascular risk with an established stable atherosclerotic CVD treated at an outpatient cardiology clinic. Gas chromatography was used to evaluate the FA composition in serum phospholipids in both groups.

**RESULTS** The final analysis included 52 patients with acute MI and 74 controls. In both groups, saturated FAs constituted the largest fraction of serum phospholipid FAs (median, 1574.67  $\mu\text{mol/l}$ ), followed by n-6 PUFAs (median, 1106.99  $\mu\text{mol/l}$ ). The levels of total saturated FAs, monounsaturated FAs, n-6 PUFAs, as well as the ratio of n-6 to n-3 PUFAs significantly differed between groups. Palmitic acid constituted the largest fraction of serum phospholipids both in patients and controls (31.9% and 31.16%, respectively). In a multivariate logistic regression analysis, body mass index, low-density lipoprotein cholesterol, aspartate aminotransferase, high-sensitivity C-reactive protein, and palmitoleic and eicosadienoic acids were independently associated with MI.

**CONCLUSIONS** We showed major differences in the FA composition of serum phospholipids between patients with acute MI and high-risk individuals with stable atherosclerotic CVD. Eicosadienoic and palmitoleic acids, apart from typical cardiovascular risk factors, were independently associated with MI.

**INTRODUCTION** Previous landmark studies revealed the beneficial effect of n-3 polyunsaturated fatty acids (PUFAs) in patients with stable atherosclerotic cardiovascular disease (CVD).<sup>1-4</sup> Serum concentrations of n-3 PUFAs were shown to be inversely correlated with all-cause mortality, independently of cardiovascular risk factors.<sup>4</sup> However, with the improvement in optimal cardiovascular therapy, the results of subsequent

randomized controlled trials have questioned the beneficial impact revealed by previous observational and interventional studies.<sup>1-3</sup> It was shown that type 2 diabetes (T2D) could reduce this positive effect, at least in patients with established atherosclerotic CVD.<sup>5-8</sup> Since then, there have been conflicting reports on the association between n-3 PUFAs and cardiovascular events.<sup>4,9-11</sup> A systematic review of randomized

Correspondence to:  
Grzegorz Gajos, MD, PhD,  
Department of Coronary Disease  
and Heart Failure, Institute  
of Cardiology, Jagiellonian  
University Medical College,  
ul. Prądnicka 80, 31-202 Kraków,  
Poland, phone: +48 12 614 22 18,  
email: grzegorz.gajos@uj.edu.pl  
Received: May 19, 2019.

Revision accepted: August 5, 2019.

Published online: August 5, 2019.  
Kardiologia Pol. 2019; 77 (10): 935-943  
doi:10.33963/KP.14923

Copyright by the Author(s), 2019

## WHAT'S NEW?

The beneficial effects of polyunsaturated fatty acids (PUFAs) observed in previous landmark studies have been questioned by recent improvements in optimal cardiovascular therapy. We investigated the fatty acid (FA) composition in serum phospholipids in patients in the acute phase of myocardial infarction (MI) and patients at high cardiovascular risk with established atherosclerotic cardiovascular disease, using gas chromatography. The levels of total saturated FAs, monounsaturated FAs, n-6 PUFAs, and the ratio of n-6 to n-3 PUFAs were significantly higher in the MI group. Interestingly, there were no significant differences in n-3 PUFA levels. A multivariate analysis demonstrated that palmitoleic and eicosadienoic acids (together with other factors such as body mass index, low-density lipoprotein cholesterol, aspartate aminotransferase, high-sensitivity C-reactive protein) were independently associated with MI, which is a novel finding.

controlled trials did not find any significant effects of n-3 PUFAs on mortality or cardiovascular events.<sup>12</sup> However, a recently published REDUCE-IT study (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) brought our attention to the proper dosage of icosapentaenoic acid (EPA) ethyl ester in high-risk patients with established atherosclerotic CVD or T2D, and demonstrated a significant reduction of cardiovascular mortality.<sup>13,14</sup> Therefore, we sought to investigate the differences in fatty acid (FA) composition in serum phospholipids between patients with an established acute phase of myocardial infarction (MI) and high-risk patients with stable atherosclerotic CVD, and to assess the predictive value of these FAs in the diagnosis of MI.

## METHODS Study population Myocardial infarction group

We assessed 83 patients hospitalized within 12 hours from the onset of the first clinical symptoms of MI. We included both patients with ST-segment elevation MI (STEMI) and those with non-ST-segment elevation MI (NSTEMI). The inclusion criteria were the diagnosis of STEMI or NSTEMI and age of 45 years or older. Both STEMI and NSTEMI diagnoses were established according to the Third Universal Definition of Myocardial Infarction.<sup>15-23</sup> The exclusion criteria were as follows: prior n-3 PUFA treatment, known sensitivity or allergy to fish or PUFA supplements (or other conditions resulting in the lack of dietary intake of n-3 or n-6 PUFAs), pregnancy, active bleeding, acute infection, serum creatinine levels higher than 177  $\mu\text{mol/l}$  (2 mg/dl), liver injury (alanine transaminase levels >1.5 times above the upper limit of the reference range), alcohol or drug abuse, history of malignancy (unless disease free for >10 years or nonmelanoma skin carcinoma), life expectancy of less than 12 months due to concomitant diseases, abnormal laboratory or imaging findings that would interfere with the interpretation of the results, and any life-threatening condition during the study.

**Control group** The control group included 74 patients with established stable atherosclerotic CVD and T2D treated at an outpatient cardiology clinic. The exclusion criteria were as follows: acute coronary syndrome (within the previous 3 months), percutaneous coronary intervention or coronary artery bypass grafting (within the previous month). Other exclusion criteria were identical to those in the MI group.

The study was approved by the local ethics committee (no., KBET 122.6120.271.2015 and 122.6120.92.2015). Each patient provided written informed consent before enrollment to the study.

**Laboratory investigations** Blood samples were obtained on admission to the emergency department (MI group), or between 8 AM and 10 AM on admission to the department after overnight fasting (control group). The samples were processed 30 to 60 minutes after blood collection and stored at  $-70^{\circ}\text{C}$  until further analysis. Blood was taken from the antecubital vein with minimal stasis. Routine blood tests, including the measurement of complete blood count, lipid profile (total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides), and the levels of aspartate aminotransferase, alanine transaminase, and serum creatinine, were done by automated laboratory techniques. Glycated hemoglobin  $\text{A}_{1c}$  levels were measured using a turbidimetric inhibition immunoassay.

## Analysis of fatty acid composition in serum phospholipids

The analytical procedure consisted of a few separate steps: 1) extraction of serum total lipids; 2) separation of the lipid fraction on Sep-PakNH2 columns (Waters, Milford, Massachusetts, United States); 3) methylation and separation of the FA from the phospholipid fraction by gas chromatography (6890N Network GC Systems, Agilent Technologies, Wilmington, Delaware, United States) equipped with an Agilent J&W HP-88 capillary column (100 m, 0.250 mm, 0.20  $\mu\text{m}$ ) (Agilent Technologies). As an internal standard, 1,2-dipentadecanoin-sn-glicero-3-phosphocholine was used (Sigma-Aldrich, Steinheim, Germany). The method was calibrated using a calibration mixture (all FAs, Sigma-Aldrich). The serum levels of saturated FAs (SFAs) (lauric, C12:0; myristic, C14:0; palmitic, C16:0; stearic, C18:0; and lignoceric, C24:0) and unsaturated acids (n-7 [palmitoleic (POA), C16:1], n-9 [oleic, C18:1], n-3 [ $\alpha$ -linolenic (ALA), C18:3; EPA, C20:5; and DHA, C22:6], and n-6 [linoleic (LA), C18:2; eicosadienoic (EDA), C20:2; and arachidonic (AA), C20:4] of the phospholipid fraction were quantitatively measured by gas chromatography. The serum concentration of FAs of the phospholipid

fraction was expressed as  $\mu\text{mol/l}$ . All laboratory tests were performed by investigators blinded to the sample origin.

**Statistical analysis** Categorical variables were presented as numbers and percentages. Continuous variables were expressed as mean (SD) or median and interquartile range (IQR). Differences between groups were compared using the Student or Welch *t* test, depending on the equality of variances for normally distributed variables. The Mann–Whitney test was used for nonnormally distributed continuous variables. Normality was assessed by the Shapiro–Wilk test. The equality of variances was assessed using the Levene test. Categorical variables were compared by the Fisher exact test for  $2 \times 2$  tables or by the Pearson  $\chi^2$  test for other tables. The Pearson correlation coefficient was computed to measure the linear dependence between 2 normally distributed variables. The Spearman rank correlation coefficient was calculated to measure monotonic trends between 2 variables if the distribution of the variables was nonnormal.

All baseline characteristics, as well as laboratory investigations and fatty acid concentrations, were assessed as potential predictors of MI using a univariate logistic regression analysis. If a *P* value from simple logistic regression for a specific variable was 0.15 or lower, the variable was included in a multiple logistic regression model. Two-sided *P* values of less than 0.05 were considered significant. All calculations were done with JMP, version 14.0.0 (SAS Institute Inc., Vienna, Austria, 2018).

In cases of possibility of separation problems in logistic regression, the Firth bias-adjusted method was used. This maximum likelihood-based method has been shown to produce better estimates and tests than maximum likelihood-based models that do not use bias correction. In addition, bias correction ameliorates separation problems that tend to occur in logistic-type models.

**RESULTS Baseline characteristics** The final analysis included 52 patients in the MI group and 74 controls. The baseline characteristics of the study patients, including comorbidities and medication use, are shown in TABLE 1. We did not observe any differences in age, sex, current smoking status, prior MI, hypertension, and chronic kidney disease between groups. However, the percentage of patients with obesity, T2D, and use of antidiabetic medication was higher in the MI than in the control group (TABLE 1). In addition, as expected, there were significant differences between groups in high-sensitivity C-reactive protein (hs-CRP) levels, lipid profile (TABLE 2), left ventricular ejection fraction, as well as the use of some of the drugs, for example, clopidogrel or acetylsalicylic acid (TABLE 1).

**Fatty acid composition in serum phospholipids** Saturated FAs constituted the largest fraction of serum phospholipid FAs both in the MI and control groups (median,  $1574.67 \mu\text{mol/l}$  [IQR,  $1402.43$ – $1855.81 \mu\text{mol/l}$ ] and  $1441.56 \mu\text{mol/l}$  [IQR,  $1282.93$ – $1599.76 \mu\text{mol/l}$ ], respectively), followed by n-6 PUFAs as the second (median,  $1106.99 \mu\text{mol/l}$  [IQR,  $986.84$ – $1264.19 \mu\text{mol/l}$ ] and median,  $1004.72 \mu\text{mol/l}$  [IQR,  $877.78$ – $1118.32 \mu\text{mol/l}$ ], respectively). Interestingly, in the MI group, the third major fraction of serum phospholipids were monosaturated FAs (MUFAs) (median,  $348.48 \mu\text{mol/l}$  [IQR,  $299.82$ – $443.54 \mu\text{mol/l}$ ]), while in the control group, n-3 PUFAs (median,  $359.11 \mu\text{mol/l}$  [IQR,  $280.13$ – $425.70 \mu\text{mol/l}$ ]).

Significant differences between the MI and control groups were found for every type of the FA fraction of serum phospholipids, including SFAs, MUFAs, n-3 PUFAs, and n-6 PUFAs (TABLE 3). Importantly, total SFAs, MUFAs, n-6 PUFA, as well as the ratio of n-6 to n-3 PUFAs significantly differed between groups (FIGURE 1A–1G), while there were no significant differences in DHA and EPA concentrations.

Considering single FAs, palmitic acid constituted the largest fraction of serum phospholipids: 31.9% and 31.16% in the MI and control groups, respectively. In the MI group, LA and AA were the second and third largest fractions of serum phospholipids (16.4% and 15.8%, respectively). In the control group, AA was the second largest fraction, while LA constituted the third largest fraction (17.6% and 14.4%, respectively) (TABLE 3).

**Univariate and multivariate logistic regression analyses** Significant predictors of MI in the study population are presented in TABLE 4. The multivariate logistic regression analysis demonstrated that body mass index, LDL-C, aspartate aminotransferase, hs-CRP, POA (C16:1), and EDA (C20:2) were independently associated with MI (TABLE 4). The predictive model showed a high degree of cross-validated calibration and discrimination, with an area under the curve of 0.99.

**DISCUSSION** In our study, we demonstrated that patients with MI had significantly increased concentrations of total n-6 PUFAs, total SFAs, total MUFAs, and an increased ratio of n-6 to n-3 PUFAs when compared with patients with stable atherosclerotic CVD. Furthermore, to the best of our knowledge, this is the first study to show that the concentrations of POA (MUFA) and EDA (n-6 PUFA) are independent predictors of MI. We found that higher concentrations of both FAs, together with known cardiovascular risk factors such as LDL-C and hs-CRP levels, were significantly associated with MI.

It was previously shown that the FA composition of serum phospholipids is dependent on

**TABLE 1** Characteristics of patients with myocardial infarction, controls with stable atherosclerotic cardiovascular disease, and the whole study population

Variable	MI group (n = 52)	Control group (n = 74)	Total population (n = 126)	P value
Age, y, mean (SD)	67.98 (11.67)	65.58 (6.84)	66.57 (9.18)	0.19
Male sex	36 (69.23)	48 (64.86)	84 (66.67)	0.61
Weight, kg	81.5 (70–90)	90.20 (81.05–100)	87 (75.1–98)	0.001
Waist circumference, cm, mean (SD)	99.76 (14.64)	106 (9.66)	103.48 (12.26)	0.01
BMI, kg/m <sup>2</sup>	27.40 (25.19–31)	31.00 (27.83–33.30)	29.90 (26.55–32.85)	0.001
Previous MI	12 (23.08)	9 (25)	21 (23.86)	0.84
Obesity	24 (46.15)	43 (58.11)	67 (53.17)	0.02
Current smoking	17 (32.69)	4 (21.05)	21 (29.58)	0.34
Type 2 diabetes	19 (36.54)	74 (100)	93 (73.81)	0.001
Hypertension	47 (90.38)	62 (83.78)	109 (86.51)	0.29
Hypercholesterolemia	50 (96.15)	50 (67.57)	100 (79.37)	0.001
Hypertriglyceridemia	6 (11.54)	27 (36.49)	33 (26.19)	0.002
Heart failure	31 (62)	6 (31.58)	37 (53.62)	0.02
Chronic kidney disease	11 (21.15)	9 (12.16)	20 (15.87)	0.17
Left ventricular ejection fraction, %	48 (40–55)	60 (50–62.8)	50 (45–60)	0.001
Systolic BP, mm Hg	142.5 (128.75–163)	140 (130–150)	140 (130–155.25)	0.39
Diastolic BP, mm Hg	86 (78.25–94.75)	80 (75–86.25)	84.5 (75–90)	0.046
Medication				
β-Blocker	42 (80.77)	59 (79.73)	101 (80.16)	0.89
ACEI	43 (82.69)	50 (67.57)	93 (73.81)	0.06
ARB	4 (7.69)	16 (21.62)	20 (15.87)	0.04
Clopidogrel	46 (88.46)	33 (44.59)	79 (62.70)	0.001
Ticagrelor	1 (1.92)	0 (0)	1 (0.79)	0.23
ASA	51 (98.08)	65 (87.84)	116 (92.06)	0.04
Nitrate	4 (7.69)	11 (14.86)	15 (11.9)	0.22
CCB	8 (15.38)	31 (41.89)	39 (30.95)	0.002
Fibrate	0 (0)	1 (1.35)	1 (0.79)	0.4
Loop diuretic	16 (30.77)	9 (12.16)	25 (19.84)	0.02
Diuretic	5 (9.62)	21 (28.38)	26 (20.63)	0.01
MRA	18 (34.62)	9 (12.16)	27 (21.43)	0.003
Statin	49 (94.23)	64 (86.49)	113 (89.68)	0.16
Metformin	9 (17.31)	48 (64.86)	57 (45.24)	0.001
Insulin	7 (13.46)	32 (43.24)	39 (30.95)	0.001
Acarbose	0 (0)	3 (4.05)	3 (2.38)	0.14
DPP-4 inhibitor	0 (0)	1 (1.35)	1 (0.80)	0.41
Sulphonylurea	4 (7.69)	31 (41.89)	35 (27.78)	0.001

Data are presented as number (percentage) or median (interquartile range) unless otherwise indicated.

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; DPP-4, dipeptidyl peptidase 4; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist

**TABLE 2** Baseline laboratory test results of the study groups

Variable	MI group (n = 52)	Control group (n = 74)	Total population (n = 126)	P value
Creatinine, $\mu\text{mol/l}$	87 (73.25–107)	84 (77–93.25)	84 (75.5–94.25)	0.28
hs-TnT, $\mu\text{g/l}$	1.39 (0.25–5.76)	–	–	–
HbA <sub>1c</sub> , %	–	7 (6.6–7.5)	–	–
Glucose, mmol/l	6.9 (5.73–10.8)	–	–	–
TC, mmol/l	4.96 (4.33–5.79)	3.77 (3.22–4.34)	4.21 (3.44–5.1)	0.001
LDL-C, mmol/l	3.44 (2.71–4)	1.92 (1.52–2.65)	2.55 (1.74–3.39)	0.001
HDL-C, mmol/l	1.27 (1.08–1.65)	1.23 (0.98–1.45)	1.24 (1.02–1.56)	0.13
TG, mmol/l	1.06 (0.74–1.56)	1.38 (1.12–1.92)	1.26 (0.95–1.84)	0.005
AST, U/l	49 (29.50–91)	19 (16–23)	23 (18–32)	0.001
ALT, U/l	29.5 (24.75–40.25)	22 (14–28)	25 (17–33.75)	0.001
hs-CRP, mg/l	4.46 (1.90–12.85)	1.6 (0.74–2.77)	2.12 (1.13–5.59)	0.001
eGFR, ml/min	75 (56.25–89.25)	78 (69.25–89.18)	78 (63.75–89.18)	0.21

Data are presented as median (interquartile range).

Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; eGFR, estimated glomerular filtration rate (Modification of Diet in Renal Disease formula); HbA<sub>1c</sub>, glycated hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; hs-TnT, high-sensitivity troponin T; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; others, see [TABLE 1](#)

**TABLE 3** Fatty acid composition of serum phospholipids in the study groups

Variables		MI group (n = 52)	Control group (n = 74)	P value
SFAs, μmol/l	C12:0 (lauric)	2.23 (1.01–4.03)	2.06 (1.31–3.22)	0.74
	C14:0 (myristic)	20.16 (13.17–26.56)	16.64 (14.65–19.52)	0.05
	C16:0 (palmitic)	1080.92 (954.22–1294.80)	949.92 (857.51–1073.60)	0.001
	C18:0 (stearic)	477.65 (407.48–554.74)	418.61 (349.10–489.05)	0.02
	C24:0 (lignoceric)	29.52 (23.40–35.09)	24.48 (20.29–29.42)	0.003
n-7 MUFAs	C16:1 (palmitoleic)	20.33 (14.02–30.38)	14.93 (12.11–21.08)	0.006
n-9 MUFAs	C18:1 (oleic)	329.58 (279.81–415.52)	276.71 (244.13–334.06)	0.001
n-3 PUFAs, μmol/l	C18:3 (α-linolenic)	8.85 (5.20–11.88)	6.45 (4.84–8.86)	0.01
	C20:5 (EPA)	46.17 (31.72–82.03)	62.17 (44.57–81.29)	0.10
	C22:6 (DHA)	261.52 (222.06–353.39)	285.51 (236.01–337.17)	0.41
n-6 PUFAs, μmol/l	C18:2 (linoleic)	556.93 (465.59–653.24)	438.84 (373.24–534.49)	0.001
	C20:2 (EDA)	20.03 (15.40–24.89)	16.82 (13.54–20.89)	0.01
	C20:4 (arachidonic)	533.52 (437.18–612.34)	535.12 (460.67–621.50)	0.46

Data are presented as median (interquartile range).

Abbreviations: DHA, docosahexaenoic acid; EDA, eicosadienoic acid; EPA, eicosapentaenoic acid; MUFAs, monounsaturated acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids; others, see [TABLE 1](#)

the dietary intake of FAs during the previous weeks. However, in addition to diet, the FA concentration is determined by endogenous FA metabolism including FA synthesis, desaturation, elongation, retroconversion, and oxidation.<sup>6,24,25</sup>

**Saturated fatty acids** The current European Society of Cardiology guidelines on cardiovascular disease prevention in clinical practice recommend

a reduction of SFA intake to less than 10% of total energy, through replacement by PUFAs.<sup>26</sup> It was calculated that the risk of coronary artery disease (CAD) is reduced by 2% to 3% when 1% of energy intake from SFAs is replaced by PUFAs.<sup>26,27</sup> It was also shown that even isocaloric replacement of SFAs with PUFAs resulted in a reduction of LDL-C levels and the ratio of TC to HDL-C levels, which are established risk factors for CAD.<sup>28</sup> A recent



**TABLE 4** Univariate and multivariate logistic regression analyses of predictors of myocardial infarction

Variable	Univariate analysis			Multivariate analysis (AUC, 0.99)	
	OR (95% CI)	P value	AUC	OR (95% CI)	P value
Weight, kg	0.97 (0.945–0.993)	0.01	0.67	–	–
Waist circumference, cm	0.956 (0.924–0.987)	0.0046	0.66	–	–
BMI, kg/m <sup>2</sup>	0.856 (0.773–0.940)	0.0008	0.70	0.24 (0.2–0.56)	<0.0001
Creatinine, µmol/l	1.016 (1.001–1.034)	0.02	0.56	–	–
Heart failure, n (%)	3.535 (1.189–11.559)	0.02	0.65	–	–
Type 2 diabetes, n (%)	0.0039 (0.00003–0.03) <sup>a</sup>	<0.0001	0.82	–	–
LVEF, %	0.883 (0.805–0.949)	0.0001	0.78	–	–
Diastolic BP, mmHg	1.031 (1.004–1.062)	0.03	0.60	–	–
Hypercholesterolemia	12 (3.32–77.158)	<0.0001	0.64	–	–
Hypertriglyceridemia	0.227 (0.079–0.568)	0.001	0.62	–	–
TC, mmol/l	2.766 (1.873–4.334)	0.0001	0.78	–	–
LDL-C, mmol/l	3.759 (2.373–6.438)	0.0001	0.82	2.34 (1.32–10.26) <sup>b</sup>	<0.0001
TG, mmol/l	0.618 (0.36–0.995)	0.048	0.65	–	–
AST, U/l	1.284 (1.164–1.463)	0.0001	0.95	1.92 (1.26–5.03)	<0.0001
ALT, U/l	1.08 (1.041–1.129)	0.0001	0.76	–	–
hs-CRP, mg/l	1.099 (1.035–1.199)	0.0001	0.75	1.35 (1.04–2.40)	0.001
C14:0 (myristic), µmol/l	1.066 (1.016–1.126)	0.009	0.60	–	–
C16:0 (palmitic), µmol/l	1.003 (1.001–1.004)	0.002	0.67	–	–
C18:0 (stearic), µmol/l	1.004 (1.001–1.008)	0.02	0.62	–	–
C24:0 (lignoceric), µmol/l	1.076 (1.027–1.133)	0.002	0.66	–	–
C16:1 (palmitoleic), µmol/l	1.051 (1.017–1.091)	0.003	0.64	1.48 (1.13–2.61)	0.001
C18:1 (oleic), µmol/l	1.008 (1.004–1.014)	0.0002	0.69	–	–
C18:2 (linoleic), µmol/l	1.006 (1.003–1.01)	0.0001	0.73	–	–
C18:3 (α-linolenic), µmol/l	1.091 (1.006–1.194)	0.03	0.63	–	–
C20:2 (EDA), µmol/l	1.078 (1.018–1.145)	0.01	0.63	0.32 (0.05–0.68)	<0.0001
Total SFAs µmol/l	1.002 (1.001–1.003)	0.003	0.66	–	–
Total n-6 PUFAs µmol/l	1.002 (1.000–1.004)	0.02	0.65	–	–


**a** Values calculated with the Firth bias-adjusted method; **b** Per 0.1-unit increase

Abbreviations: AUC, area under the curve; CI, confidence interval; LVEF, left ventricular ejection fraction; OR, odds ratio; see TABLES 1, 2, and 3

analysis of EPIC-Norfolk and EPIC-Denmark cohorts by Praagman et al<sup>29</sup> suggested that a higher consumption of C4:0–C10:0, C12:0, and C14:0 was associated with a lower MI risk. The conflicting evidence on the association between SFAs and CAD could be due to differences in the types of SFAs, based on their carbon-atom chain lengths.<sup>29</sup> In our study, the majority of SFAs were inversely correlated with MI; however, the levels of lauric acid (C12:0), with the longest carbon-atom chain in our study, were similar between groups.

**Monosaturated fatty acids** Interventional studies demonstrated that MUFAs could improve cardiovascular risk factors, but

prospective data with regard to CAD risk are limited and remain controversial.<sup>30–33</sup> It was found that the total intake of MUFAs is significantly inversely correlated with total mortality, but no association with CAD was observed.<sup>34</sup> Some authors underline the role of MUFA origin for their impact on CVDs.<sup>31</sup> The replacement of SFAs with plant-based MUFAs was associated with a significantly lower risk of CAD when compared with animal-based MUFAs.<sup>31</sup> Some epidemiologic evidence suggests that the length of carbon chains in MUFAs might play a role in the prediction of CVDs.<sup>35</sup> Li et al<sup>135</sup> demonstrated that the higher concentrations of long-chain (14–18 carbon atoms) MUFAs



**FIGURE 1** Distribution of fatty acid composition in serum phospholipids in patients in the acute phase of myocardial infarction (MI) and in the control group: **A** – total saturated fatty acids (SFAs); **B** – total monounsaturated fatty acids (MUFAs); **C** – total n-3 polyunsaturated fatty acids (PUFAs); **D** – total n-6 (PUFAs); **E** – the ratio of n-6 to n-3 PUFAs; **F** – the ratio of eicosadienoic to arachidonic acid (EPA/AA); **G** – the ratio of docosahexaenoic to arachidonic acid (DHA/AA). Boxes represent median and interquartile ranges; whiskers, highest and lowest values; and dots, outliers  $>1.5$  IQR above the upper quartile.

had a beneficial impact on all-cause and cardiovascular mortality, while very long-chain MUFAs ( $\geq 20$  carbon atoms) contributed to higher mortality rates.

**n-3 Polyunsaturated fatty acids** In our study, only the ALA (C18:3) concentration was significantly higher in the MI group. We did not observe any significant differences between other n-3 PUFAs, including DHA and EPA. A recent systematic review of randomized control trials demonstrated no beneficial effects of n-3 PUFAs on mortality or cardiovascular events.<sup>12</sup> In the VITAL study (Vitamin D and Omega-3 Trial; treatment with 1 g/d of n-3 PUFAs) on primary cardiovascular prevention, the authors found a significant 19% reduction of major adverse cardiovascular events, but only in patients with low fish consumption.<sup>36</sup> On the contrary, the REDUCE-IT trial, which investigated the impact of high-dose n-3 PUFAs (4 g/d; pure EPA ethyl ester) on established CVD or T2D and other cardiovascular risk factors, demonstrated significant benefits of an intervention with n-3 PUFAs, including a reduction in major adverse cardiovascular events by 25%.<sup>13</sup> Finally, the membrane composition of FAs (especially EPA and DHA) in the inflammatory cells could alter cell function. Therefore, the anti-inflammatory impact of those acids may contribute to their protective actions against an atherosclerotic process and plaque rupture.<sup>37</sup>

**n-6 Polyunsaturated fatty acids (PUFAs) and the ratio of n-6 to n-3 PUFAs** A multicenter trial by Nishizaki et al.<sup>38</sup> found that a low ratio of EPA to AA levels, but not of DHA to AA levels, was significantly associated with the occurrence of MI. In our study, these ratios were similar in both groups. Nevertheless, we observed that the ratio of n-6 to n-3 PUFAs and total n-6 PUFA levels were much higher in the MI group than in controls.

It was reported that the LA concentration was inversely associated with the occurrence of MI.<sup>39</sup> Moreover, it was shown that low serum levels of n-6 PUFAs could predict a poor long-term prognosis in patients with acute CVD. In particular, decreased dihomo- $\gamma$ -linolenic acid (DGLA) levels were associated with increased total mortality rates in patients with acute CVD. However, DGLA and AA have the opposite effects, mainly due to their metabolites. The pro-inflammatory effect of AA comes from the conversion to series-2 prostaglandins and series-4 leukotrienes, which are known to induce platelet aggregation, inflammation, and vasoconstriction.<sup>40,41</sup> On the other hand, DGLA undergoes oxidative metabolism to anti-inflammatory eicosanoids (series-1 prostaglandin and series-3 leukotrienes).<sup>40,42-44</sup>

**Palmitoleic and eicosadienoic acids** Although previous studies have discussed the impact of POA levels on the risk and progression of atherosclerotic CVD,<sup>45,46</sup> none of them analyzed the effect of POA in patients with MI. Palmitoleic acid was found to act as a lipokine and could be considered as a metabolic modulator.<sup>47</sup> Furthermore, POA was associated with decreased LDL-C and fibrinogen levels as well as increased HDL-C levels.<sup>47-49</sup>

We did not identify any studies regarding the association between EDA levels and the acute phase of MI. Eicosadienoic acid is a naturally occurring n-6 polyunsaturated FA and a relatively minor metabolite of LA. It can be further metabolized to, for example, AA, thereby giving it proinflammatory properties.<sup>50</sup> In our study, we demonstrated a novel association between EDA levels in patients with acute phase MI.

**Limitations** First, the cross-sectional design of the study did not allow us to infer causality, and there was no follow-up. Second, our patients were provided with dietary advice regarding low-fat and low-carbohydrate meals, but dietary fat intake was not determined. Third, the higher presence of obesity and T2D in the control group could affect the inference between groups. Finally, the multiple logistic regression model for MI per 1-unit increase in EDA showed opposite results to those of the simple logistic regression model for EDA, which was confirmed also after eliminating the observations with the highest influence on the model (Cook's distance). This could be the so called Simpson's paradox resulting from adjustment for known risk factors, such as LDL-C.

**Conclusions** The major differences in the FA composition of serum phospholipids between patients with MI and high-risk individuals with stable atherosclerotic CVD and T2D were the higher content of SFAs, MUFAs, n-6 PUFAs, as well as the ratio of n-6 to n-3 PUFAs. In the multivariate analysis, apart from known cardiovascular risk factors, EDA and POA levels were independent predictors of MI.

## ARTICLE INFORMATION

**CONFLICT OF INTEREST** None declared.

**OPEN ACCESS** This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for non-commercial purposes only. For commercial use, please contact the journal office at [kardiologiapolska@ptkardio.pl](mailto:kardiologiapolska@ptkardio.pl).

**HOW TO CITE** Siniarski A, Rostoff P, Rychlak R, et al. Unsaturated fatty acid composition in serum phospholipids in patients in the acute phase of myocardial infarction. *Kardiologia Polska*. 2019; 77: 935-943. doi:10.33963/KP.14923

## REFERENCES

- 1 Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids



- after PCI to modify responsiveness to dual antiplatelet therapy) study. *J Am Coll Cardiol*. 2010; 55: 1671-1678.
- 2 Gajos G, Zalewski J, Nessler J, et al. Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. *Kardiologia Pol*. 2012; 70: 439-445.
  - 3 Gajos G, Zalewski J, Mostowik M, et al. Polyunsaturated omega-3 fatty acids reduce lipoprotein-associated phospholipase A2 in patients with stable angina. *Nutr Metab Cardiovasc Dis*. 2014; 24: 434-439.
  - 4 Pottala JV, Garg S, Cohen BE, et al. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the heart and soul study. *Circ Cardiovasc Qual Outcomes*. 2010; 3: 406-412.
  - 5 Siniarski A, Haberk M, Mostowik M, et al. Treatment with omega-3 polyunsaturated fatty acids does not improve endothelial function in patients with type 2 diabetes and very high cardiovascular risk: a randomized, double-blind, placebo-controlled study (Omega-FMD). *Atherosclerosis*. 2018; 271: 148-155.
  - 6 Poreba M, Rostoff P, Siniarski A, et al. Relationship between polyunsaturated fatty acid composition in serum phospholipids, systemic low-grade inflammation, and glycemic control in patients with type 2 diabetes and atherosclerotic cardiovascular disease. *Cardiovasc Diabetol*. 2018; 17: 29.
  - 7 Poreba M, Mostowik M, Siniarski A, et al. Treatment with high-dose n-3 PU-FAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. *Cardiovasc Diabetol*. 2017; 16: 50.
  - 8 Gajos G. Diabetes and cardiovascular disease: from new mechanisms to new therapies. *Pol Arch Intern Med*. 2018; 128: 178-186.
  - 9 Kromhout D, Giltay EJ, Geleijnse JM. n-3 Fatty acids and cardiovascular events after myocardial infarction. *N Engl J Med*. 2010; 363: 2015-2026.
  - 10 Einvik G, Klemsdal TO, Sandvik L, Hjerkin EM. A randomized clinical trial on n-3 polyunsaturated fatty acids supplementation and all-cause mortality in elderly men at high cardiovascular risk. *Eur J Cardiovasc Prev Rehabil*. 2010; 17: 588-592.
  - 11 GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. *Lancet*. 1999; 354: 447-455.
  - 12 Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2018; 11: CD003177.
  - 13 Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med*. 2019; 380: 11-22.
  - 14 Gajos G. Omega-3 polyunsaturated fatty acids: is their future VITALized or REDUCED? *Cardiovasc Res*. 2019; 115: e58-e60.
  - 15 Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. *Eur Heart J*. 2012; 33: 2551-2567.
  - 16 Destefano CM, Schneider DJ. Antiplatelet therapy for patients undergoing coronary artery bypass surgery. *Kardiologia Pol*. 2018; 76: 945-952.
  - 17 Kleczyński P, Siudak Z, Dziewierz A, et al. The network of invasive cardiology facilities in Poland in 2016 (data from the ORPKI Polish National Registry). *Kardiologia Pol*. 2018; 76: 805-807.
  - 18 Parma AZ, Young R, Roleder T, et al. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease in the CLARIFY registry versus other European countries. *Pol Arch Intern Med*. 2019; 129: 327-334.
  - 19 Karwowski J, Gierlotka M, Gąsior M, et al. Relationship between infarct artery location, acute total coronary occlusion, and mortality in STEMI and NSTEMI patients. *Pol Arch Intern Med*. 2017; 127: 401-411.
  - 20 Podolec J, Wiewiórka Ł, Siudak Z, et al. Prevalence and clinical presentation of myocardial bridge on the basis of the National Polish Percutaneous Interventions Registry and the Classification of Rare Cardiovascular Diseases. *Kardiologia Pol*. 2018; 77: 465-470.
  - 21 Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization [in Polish]. *Kardiologia Pol*. 2018; 76: 1585-1664.
  - 22 Kinnaird T, Mamas MA. Treatment of patients with diffuse coronary disease: a challenge yet to be solved? *Pol Arch Intern Med*. 2019; 129: 365-366.
  - 23 Molek AP, Włodarczyk A, Gajos G, et al. Simultaneous cardiac free wall rupture and ventricular septal rupture following acute myocardial infarction treated with emergency balloon closure. *Pol Arch Intern Med*. 2019 Sep 17. [Epub ahead of print].
  - 24 Kahleova H, Malinska H, Kazdova L, et al. The effect of meal frequency on the fatty acid composition of serum phospholipids in patients with type 2 diabetes. *J Am Coll Nutr*. 2016; 35: 317-325.
  - 25 Cho JS, Baek SH, Kim JY, et al. Serum phospholipid monounsaturated fatty acid composition and Δ-9-desaturase activity are associated with early alteration of fasting glycemic status. *Nutr Res*. 2014; 34: 733-741.
  - 26 Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2016; 37: 2315-2381.
  - 27 Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med*. 2010; 7: e1000252.
  - 28 Baum SJ, Kris-Etherton PM, Willett WC, et al. Fatty acids in cardiovascular health and disease: A comprehensive update. *J Clin Lipidol*. 2012; 6: 216-234.
  - 29 Praagman J, Vissers LET, Mulligan AA, et al. Consumption of individual saturated fatty acids and the risk of myocardial infarction in a UK and a Danish cohort. *Int J Cardiol*. 2019; 279: 18-26.
  - 30 Guasch-Ferré M, Babio N, Martínez-González MA, et al. Dietary fat intake and risk of cardiovascular disease and all-cause mortality in a population at high risk of cardiovascular disease. *Am J Clin Nutr*. 2015; 102: 1563-1573.
  - 31 Zong G, Li Y, Sampson L, et al. Monounsaturated fats from plant and animal sources in relation to risk of coronary heart disease among US men and women. *Am J Clin Nutr*. 2018; 107: 445-453.
  - 32 Chowdhury R, Warnakula S, Kunutsor S, et al. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med*. 2014; 160: 398-406.
  - 33 Zong G, Li Y, Wanders AJ, et al. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. *BMJ*. 2016; 355: i5796.
  - 34 De Souza RJ, Mente A, Maroleanu A, et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. *BMJ*. 2015; 351: h3978.
  - 35 Li Z, Zhang Y, Su D, et al. The opposite associations of long-chain versus very long-chain monounsaturated fatty acids with mortality among patients with coronary artery disease. *Heart*. 2014; 100: 1597-1605.
  - 36 Manson JE, Cook NR, Lee I-M, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. *N Engl J Med*. 2019; 380: 23-32.
  - 37 Calder PC. The role of marine omega-3 (n-3) fatty acids in inflammatory processes, atherosclerosis and plaque stability. *Mol Nutr Food Res*. 2012; 56: 1073-1080.
  - 38 Nishizaki Y, Shimada K, Tani S, Ogawa T. Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. *Am J Cardiol*. 2014; 113: 441-445.
  - 39 Block RC, Harris WS, Reid KJ, Spertus JA. Omega-6 and trans fatty acids in blood cell membranes: a risk factor for acute coronary syndromes? *Am Heart J*. 2008; 156: 1117-1123.
  - 40 Ouchi S, Miyazaki T, Shimada K, et al. Decreased circulating dihomogamma-linolenic acid levels are associated with total mortality in patients with acute cardiovascular disease and acute decompensated heart failure. *Lipids Health Dis*. 2017; 16: 150.
  - 41 Marion-Letellier R, Savoye G, Ghosh S. Polyunsaturated fatty acids and inflammation. *IUBMB Life*. 2015; 67: 659-667.
  - 42 Kapoor R, Huang Y-S. Gamma linolenic acid: an antiinflammatory omega-6 fatty acid. *Curr Pharm Biotechnol*. 2006; 7: 531-534.
  - 43 Russo GL. Dietary n-6 and n-3 polyunsaturated fatty acids: from biochemistry to clinical implications in cardiovascular prevention. *Biochem Pharmacol*. 2009; 77: 937-946.
  - 44 Al-Khudairy L, Hartley L, Clar C, et al. Omega 6 fatty acids for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2015; 11: CD011094.
  - 45 Djoussé L, Matthan NR, Lichtenstein AH, Gaziano JM. Red blood cell membrane concentration of cis-palmitoleic and cis-vaccenic acids and risk of coronary heart disease. *Am J Cardiol*. 2012; 110: 539-544.
  - 46 Watts GF, Jackson P, Burke V, Lewis B. Dietary fatty acids and progression disease in men. *Am J Clin Nutr*. 1996; 64: 202-209.
  - 47 Frigolet ME, Gutiérrez-Aguilar R. The role of the novel lipokine palmitoleic acid in health and disease. *Adv Nutr*. 2017; 8: 173-181.
  - 48 Paillard F, Catheline D, Le Duff F, et al. Plasma palmitoleic acid, a product of stearoyl-CoA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. *Nutr Metab Cardiovasc Dis*. 2008; 18: 436-440.
  - 49 Mozaffarian D, Cao H, King IB, et al. Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes. *Am J Clin Nutr*. 2010; 92: 1350-1358.
  - 50 Huang YS, Huang WC, Li CW, Chuang LT. Eicosadienoic acid differentially modulates production of pro-inflammatory modulators in murine macrophages. *Mol Cell Biochem*. 2011; 358: 85-94.